TH Theratechnologies Inc

Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on development and commercialization of innovative therapies, today announced three upcoming poster presentations at IDWeek 2024, taking place October 16-19 in Los Angeles, Calif.

One poster presents data linking excess visceral abdominal fat (EVAF) to increased cardiovascular risk in people with HIV, while a second poster documents how use of tesamorelin, a growth hormone-releasing factor (GHRF) analog, to reduce EVAF can lower cardiovascular disease risk in persons with HIV. Another poster reports on the study design and baseline characteristics of the PROMISE-US trial, an observational, real-world study of ibalizumab, a CD4-directed post-attachment inhibitor of HIV, in heavily treatment-experienced patients with multidrug resistance.

“The IDWeek poster presentations shed new light on important medical issues facing people with HIV,” said Christian Marsolais, Ph.D., Senior Vice President and Chief Medical Officer of Theratechnologies. “As people live longer with HIV and with greater exposure to anti-retroviral medicines, they may experience higher amounts of excess visceral abdominal fat and risk multidrug resistance. We look forward to sharing our findings with HIV clinicians and researchers at this premier meeting on infectious disease.”

Theratechnologies will present the following posters at IDWeek 2024:

Title: Impact of Tesamorelin on Cardiovascular Disease Risk Prediction Scores in Phase 3 Studies Treatment Arms: Subanalysis

• Lead Author: Steven Grinspoon, MD, Massachusetts General Hospital and Harvard Medical School, Boston, Mass.
• Date & Time: Thursday, October 17, 2024, 12:15 PM – 1:30 PM PT
• Session Title: HIV: Complications and Coinfections
• Location: Halls JK
• Poster Board Number: P-433

Title: Cardiovascular Risk Scores and Insulin Resistance are Higher with Excess Visceral Abdominal Fat in People with HIV in the Modern Antiretroviral (ART) Era.

• Presenting Author: Karam Mounzer, MD, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pa.
• Date & Time: Thursday, October 17, 2024, 12:15 PM – 1:30 PM PT
• Session Title: HIV: Complications and Coinfections
• Location: Halls JK
• Poster Board Number: P-453

Title: A Prospective and Retrospective Observational Study of Multidrug-Resistant Patient Outcomes with and without Ibalizumab in a Real-World Setting: United States (PROMISE-US) Study Design and Baseline Characteristics

• Presenting Author: Dr. Charlotte-Paige Rolle, M.D., Orlando Immunology Center and Emory Rollins School of Public Health, Orlando, Fla.
• Date & Time: Thursday October 17, 2024, 12:15 PM – 1:30 PM PT
• Session Title: HIV: Treatment
• Location: Halls JK
• Poster Board Number: P-565

IDWeek is the joint annual meeting of the Infectious Diseases Society of America, the Society for Healthcare Epidemiology of America, the HIV Medicine Association, the Pediatric Infectious Diseases Society and the Society of Infectious Diseases Pharmacists.

About Theratechnologies

Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. Further information about Theratechnologies is available on the Company's website at www.theratech.com, on SEDAR at www.sedarplus.ca and on EDGAR at www.sec.gov. Follow Theratechnologies on Linkedin and Twitter.

Forward-Looking Information

This press release contains forward-looking statements and forward-looking information (collectively, the “Forward-Looking Statements”), within the meaning of applicable securities laws, that are based on our management’s beliefs and assumptions and on information currently available to our management. You can identify Forward-Looking Statements by terms such as "may", "will", "should", "could", “promising”, “would”, "outlook", "believe", "plan", "envisage", "anticipate", "expect" and "estimate", or the negatives of these terms, or variations of them. The Forward-Looking Statements contained in this press release include, but are not limited to, statements regarding the longevity of people with HIV and its relationship with increased excess visceral abdominal fat and the risk of multi-drug resistance. Forward-looking statements involve a number of assumptions, risks and uncertainties. The Company refers current and potential investors to the “Risk Factors” section of the Company’s Form 20-F dated February 21, 2024 available on SEDAR+ at www.sedarplus.ca and on EDGAR at www.sec.gov under Theratechnologies’ public filings. The reader is cautioned to consider these and other risks and uncertainties carefully and not to put undue reliance on forward-looking statements. Forward-Looking Statements reflect current expectations regarding future events and speak only as of the date of this press release and represent the Company’s expectations as of that date.

The Company undertakes no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances or otherwise, except as may be required by applicable law.

Contacts:

Media inquiries:Julie SchneidermanSenior Director, Communications & Corporate Affairscommunications@theratech.com1-514-336-7800

Investor Inquiries:Philippe DubucSenior Vice President and Chief Financial Officerpdubuc@theratech.com438-315-6608